Wuhan Healthgen Biotechnology (SHSE:688765) Cyclically Adjusted Revenue per Share: ¥0.14 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688765 Wuhan Healthgen Biotechnology Corp SHSE:688765
21 GF Score
Price ¥38.50
! 7 Warning Signs
View Full Analysis

What is Wuhan Healthgen Biotechnology Cyclically Adjusted Revenue per Share?

Wuhan Healthgen Biotechnology SHSE:688765 -1.28% 21 Cyclically Adjusted Revenue per Share is ¥0.14 as of Mar. 2026. GuruFocus rates SHSE:688765 with a GF Score™ of 21/100. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Wuhan Healthgen Biotechnology's adjusted revenue per share data for the fiscal year that ended in Dec. 2025 was ¥0.169. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥0.14 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-30), Wuhan Healthgen Biotechnology's current stock price is ¥ 38.50. Wuhan Healthgen Biotechnology's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec. 2025 was ¥0.14. Wuhan Healthgen Biotechnology's Cyclically Adjusted PS Ratio of today is 275.00.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Wuhan Healthgen Biotechnology was 578.21. The lowest was 266.02. And the median was 514.57.


Wuhan Healthgen Biotechnology  (SHSE:688765) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Wuhan Healthgen Biotechnology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=38.50/0.14
=275.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Wuhan Healthgen Biotechnology was 578.21. The lowest was 266.02. And the median was 514.57.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Wuhan Healthgen Biotechnology Cyclically Adjusted Revenue per Share Related Terms


Wuhan Healthgen Biotechnology Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Wuhan Healthgen Biotechnology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan Healthgen Biotechnology Cyclically Adjusted Revenue per Share Chart

Wuhan Healthgen Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.14 0.13 0.14

Wuhan Healthgen Biotechnology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Dec19 Dec20 Dec21 Jun22 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.14 0.00

SHSE:688765 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Healthgen Biotechnology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Healthgen Biotechnology Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wuhan Healthgen Biotechnology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Wuhan Healthgen Biotechnology's Cyclically Adjusted PS Ratio falls into.


SHSE:688765
21GF Score
Wuhan Healthgen Biotechnology Corp SHSE:688765
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wuhan Healthgen Biotechnology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Wuhan Healthgen Biotechnology's adjusted Revenue per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.169/115.8323*115.8323
=0.169

Current CPI (Dec. 2025) = 115.8323.

Wuhan Healthgen Biotechnology Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.063 100.600 0.073
201612 0.067 102.600 0.076
201712 0.088 104.500 0.098
201912 0.215 111.200 0.224
202012 0.433 111.500 0.450
202112 0.118 113.108 0.121
202212 0.051 115.116 0.051
202312 0.091 114.781 0.092
202412 0.094 114.893 0.095
202512 0.169 115.832 0.169

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥0.14 mean?
Wuhan Healthgen Biotechnology (SHSE:688765) has a Cyclically Adjusted Revenue per Share of ¥0.14 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Wuhan Healthgen Biotechnology and its competitors.
Is Wuhan Healthgen Biotechnology's Cyclically Adjusted Revenue per Share too high?
Wuhan Healthgen Biotechnology's current Cyclically Adjusted Revenue per Share is ¥0.14. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's Cyclically Adjusted Revenue per Share compare to ZTS?
Wuhan Healthgen Biotechnology's Cyclically Adjusted Revenue per Share of ¥0.14 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Wuhan Healthgen Biotechnology and its competitors. Wuhan Healthgen Biotechnology's current Cyclically Adjusted Revenue per Share is ¥0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current Cyclically Adjusted Revenue per Share of ¥0.14. The current Cyclically Adjusted Revenue per Share is ¥0.14. Wuhan Healthgen Biotechnology's overall GF Score™ is 21/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current Cyclically Adjusted Revenue per Share is ¥0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan Healthgen Biotechnology Business Description

Address No. 268, Shendun 5th Road, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430206
Wuhan Healthgen Biotechnology Corp is engaged in Research, development, production and commercialization of plant-based molecular medicines.
21GF Score

Get the complete analysis for SHSE:688765

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.50
Price